Journal News

Starved for oxygen, T cells flag in cancer fight

Laurel Oldach
Sept. 6, 2022

Cytotoxic T cells exist to kill cells subverted by infection or mutation. That makes them the focus of a lot of immuno-oncology research. Although cancers must slip past immune recognition to become established in the first place, immunotherapies such as checkpoint inhibitor antibodies or T cells with modified receptors can retrain the immune system to focus on cancer cells.

So far, this has worked best for blood cancers with many cells spread throughout the body. Solid tumors have been harder to treat. The inside of a tumor differs from normal tissue in complex ways that add up to make it a very immunosuppressive environment.

In a preliminary study published in Molecular & Cellular Proteomics, postdoc James Byrnes and colleagues in Jim Wells’ lab at the University of California, San Francisco, report on their research into how the proteins on the surface of a cytotoxic T cell respond to various stimuli they might encounter in a tumor.

Using primary cells removed from human blood, the team focused on the surface proteome of cytotoxic CD8+ T cells. They investigated how interactions with T regulatory cells, which dampen T cells’ response and help end an immune reaction, and oxygen limitation, a feature of many tumors, changed the cytotoxic T cell surface.

A group of killer T cells (green and red) surround a cancer cell (blue, center). When a killer T cell makes contact with a target cell, the killer cell attaches and spreads over the target, then uses special chemicals housed in vesicles (red) to deliver the killing blow. The killer T cells then move on to find the next target.
National Institutes of Health
A group of killer T cells (green and red) surround a cancer cell (blue, center). When a killer T cell makes contact
with a target cell, the killer cell attaches and spreads over the target, then uses special chemicals housed
in vesicles(red) to deliver the killing blow. The killer T cells then move on to find the next target.

T regulatory cells are abundant in some solid tumors, and the team expected them to have dramatic effects. They were surprised to find that hypoxia had a much greater effect.

“The prevailing thought is that T regulatory cells are this super-potent immunosuppressive factor,” Byrnes said. But growing CD8+ T cells with T regulatory cells changed only a targeted subset of proteins, mostly the ones that increase in abundance after activation and are involved in signaling and proliferation.

“The T-regs are reversing the activation phenotype,” Byrnes said. “Hypoxia is a little more of a sledgehammer.”

Oxygen starvation shifted cytotoxic T cell expression of many surface proteins: The cells reduced immune signaling receptors and increased metabolic proteins, apparently in an effort to survive using glycolysis. Other studies have shown that hypoxia can make T cells more prone to kill but also slower to multiply; on balance, they may become less effective.

The Wells lab is focused primarily on antibody engineering, Byrnes said, and these results have given them interesting leads to follow as they consider new ways to mobilize the immune cells within a tumor. “We’re hoping … (to) gain biological insight into what some of these proteins are doing, as well as identify handles that we can use to therapeutically engage hypoxic T cells.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Laurel Oldach

Laurel Oldach is a former science writer for the ASBMB.

Related articles

From the journals: MCP
Inayah Entzminger
From the journals: MCP
Nivedita Uday Hegdekar
From the journals: JBC
Emily Ulrich
From the journals: MCP
Krishnakoli Adhikary
From the Journals: JBC
Ken Farabaugh
From the journals: JLR
Swarnali Roy

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

CRISPR gene editing: Moving closer to home
News

CRISPR gene editing: Moving closer to home

Nov. 17, 2024

With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.

Finding a missing piece for neurodegenerative disease research
News

Finding a missing piece for neurodegenerative disease research

Nov. 16, 2024

Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.

From the journals: JLR
Journal News

From the journals: JLR

Nov. 15, 2024

Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.

Computational and biophysical approaches to disordered proteins
Award

Computational and biophysical approaches to disordered proteins

Nov. 14, 2024

Rohit Pappu will receive the 2025 DeLano Award for Computational Biosciences at the ASBMB Annual Meeting, April 12-15 in Chicago.

From lab to land: Crop modifications are fortifying our food supply against climate change
News

From lab to land: Crop modifications are fortifying our food supply against climate change

Nov. 13, 2024

Scientists explore genetic and biochemical innovations fueling future-proofing agriculture

Join the pioneers of ferroptosis at cell death conference
In-person Conference

Join the pioneers of ferroptosis at cell death conference

Nov. 13, 2024

Meet Brent Stockwell, Xuejun Jiang and Jin Ye — the co-chairs of the ASBMB’s 2025 meeting on metabolic cross talk and biochemical homeostasis research.